Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Novavax Inc — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.7, while Novavax Inc trades at $8.5 (market cap $1.38B). The key difference: Novavax Inc is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | NVAX | |
|---|---|---|
52-Week High | $75.17 | $11.19 |
52-Week Low | $72.45 | $6.22 |
Market Cap | — | $1.38B |
Sector | — | Health |
Enterprise Value | — | $889.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.50, down 0.37% with a bearish technical outlook showing 19 sell signals versus 4 buy signals. The ETF faces pressure from rising interest rate expectations, though recent dividend payments of $0.24-$0.25 provide income stability. Fixed income ETFs have seen renewed investor interest with $100 billion flowing into cash ETFs recently, indicating defensive positioning.
The bond ETF faces headwinds from potential Fed rate hikes but offers diversification benefits. Key risks include interest rate sensitivity and competition from higher-yielding alternatives. Long-term investors may find value in BND's broad market exposure and low costs despite near-term technical weakness.
Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.
The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
